Hims & Hers Health Inc. (HIMS) experienced a significant pre-market surge of 10.66%, continuing its positive momentum from the previous trading session.

The sharp rise appears driven by two major catalysts. First, the company has entered into a partnership with pharmaceutical giant Novo Nordisk, which will authorize the sale of Novo Nordisk's weight-loss drugs on the Hims platform. This marks a significant commercial milestone, expanding Hims' offerings in the high-demand weight management market.

Secondly, U.S. regulators are moving forward with plans to reassess popular peptide treatments. The Food and Drug Administration has scheduled meetings to discuss whether certain pharmacies may be allowed to produce specific peptide substances, which could make these treatments more widely available. Hims & Hers had previously indicated to investors its interest in entering the peptide space, making this regulatory development a positive signal for its future business categories.